Cancer News and Research

Latest Cancer News and Research

USPTO issues Notice of Allowance for U.S. patent application in the 'Crooke' patent family

Isis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application (No. 10/078,949) in the “Crooke” patent family, which broadly covers chemically modified RNA-containing therapeutics.

16 Dec 2009

Zecotek Photonics' proprietary TGFL selected for research in flow cytometry

Zecotek Photonics Inc., a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that the National Cancer Institute, a division of the U.S. National Institutes of Health (NIH), has selected its proprietary Tunable Green Fiber Laser (TGFL) for research in flow cytometry.

16 Dec 2009

Stress and alcohol can trigger domestic violence during holiday season

The holidays are supposed to be a time for family togetherness and cheer, yet for many women and children, they are instead a time of fear and violence.

16 Dec 2009

Results from five new studies on Genomic Health's Oncotype DX breast cancer test announced

Genomic Health, Inc. today announced results from five new studies on its Oncotype DX® breast cancer test, a multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit and recurrence risk for patients with early-stage breast cancer.

16 Dec 2009

Dendritic cell changes suggest new strategy to identify and treat debilitating lung disease

A new study links chronic obstructive pulmonary disease, or COPD, with increased activity of cells that act as sentinels to activate the body's immune system.

15 Dec 2009

BioAlliance Pharma SA to enter Phase II clinical trial for clonidine Lauriad and Phase I clinical trial for AMEP

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announces the approval from the French Drug Agency (AFFSSaPS) to enter Phase II clinical trial for clonidine Lauriad® in radiotherapy and chemotherapy-induced oral mucositis and the approval from Danish and Slovene Agencies to enter Phase I clinical trial for AMEPTM in invasive melanoma.

15 Dec 2009

Advaxis to collaborate with GOG in Phase II clinical trial of ADXS11-001

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) vaccine company, will collaborate with the Gynecologic Oncology Group (GOG), a collaborative research group of the National Cancer Institute (NCI), in a multicenter, Phase II clinical trial of the Company’s lead drug candidate, ADXS11-001 in the treatment of advanced cervix cancer in women who have failed prior cytotoxic therapy.

15 Dec 2009

Lilly Endowment offers $60 million to implement the Indiana Physician Scientist Initiative

When a patient has a disease that can't be treated effectively, the physician can see clearly where research is needed.

15 Dec 2009

University of Wisconsin IRB approves GenSpera's G-202 Phase I study for cancer

GenSpera, Inc. announced today that the Institutional Review Board (IRB) at the University of Wisconsin, in Madison, WI, has approved a Phase I study of its target activated pro-drug, G-202, for the treatment of cancer. The FDA (US Food and Drug Administration) approved the study in September. GenSpera expects to enroll the first study patient early in the first quarter of 2010.

15 Dec 2009

Encouraging results from DAVANAT in combination with chemotherapies and biologics

Pro-Pharmaceuticals, Inc. today announced that the Brussels Branch of the Ludwig Institute of Cancer Research is testing the ability of DAVANAT® to stop Galectin-3 from blocking the immune system’s action on cancer cells. Peer reviewed studies have demonstrated that Galectin-1 and Galectin-3 induce apoptosis (cell death) in immune system T cells (“Galectins,” Chapter 7, Wiley, 2008).

15 Dec 2009

Celgene announces positive data from its apremilast Phase IIb study for plaque-type psoriasis

Celgene Corporation announced clinical data from an investigational Phase IIb, double-blind, placebo-controlled study of apremilast (CC-10004) in patients with moderate-to-severe plaque-type psoriasis (PSOR-005). This was a 352-patient, multi-center study in which patients received either 10mg, 20mg or 30mg of apremilast twice per day (BID), or placebo.

15 Dec 2009

Novartis submits JOULFERON MAA to the EMEA

Human Genome Sciences, Inc. today announced that Novartis has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for approval to market JOULFERON® (albinterferon alfa-2b, known in the United States as ZALBIN™) for the treatment of chronic hepatitis C. In November 2009, HGS submitted a Biologics License Application (BLA) for ZALBIN to the FDA in the United States.

15 Dec 2009

Lytix Biopharma AS receives approval to commence Phase I clinical trials of Oncopore

The Norwegian pharmaceutical company Lytix Biopharma AS today announced approvals from the Norwegian Medicines Agency (”Statens legemiddelverk”) and the Swedish Medical Products Agency (”Läkemedelverket”) to commence Phase I clinical trials of OncoporeTM (LTX-315) for the treatment of cancer.

15 Dec 2009

Gamma Medica-Ideas signs exclusive license and commercialization agreement with Mayo Clinic

Gamma Medica-Ideas, Inc. ("GMI"), a leading developer of digital molecular imaging systems, announced today that it has signed an exclusive license and commercialization agreement with Mayo Clinic to further develop and commercialize a suite of technologies invented by a team of Mayo physicians and scientists, headed by Michael O'Connor, PhD.

15 Dec 2009

Teens, contraception and unplanned pregnancy

Nearly all unmarried young adults ages 18-29 believe pregnancy is something that should be planned (94% of men and 86% of women) and say that it is important to avoid pregnancy in their lives right now (86% of men and 88% of women), according to new research released by The National Campaign to Prevent Teen and Unplanned Pregnancy.

15 Dec 2009

Preventing tumours from making new blood vessels can also prevent spread of cancer

Patients with advanced prostate cancer are often treated with hormones, but when the tumours start growing again they have more and different blood vessels, reveals a thesis from the Sahlgrenska Academy, at the University of Gothenburg, Sweden. This discovery paves the way for new treatments for hormone-resistant prostate cancer.

15 Dec 2009

Decline in reducing youth smoking and increase in smokeless tobacco use

The 2009 Monitoring the Future Survey released today by the National Institute of Drug Abuse shows that the nation continues to make gradual progress in reducing youth smoking, but declines have slowed significantly compared to the dramatic gains early in the decade. In especially troubling news, the survey also finds that smokeless tobacco use has increased among 10th and 12th graders in recent years, a period during which tobacco companies have introduced a slew of new smokeless tobacco products and significantly increased marketing for smokeless tobacco.

15 Dec 2009

New technique may help diagnose treatments for Alzheimer's, diabetes and cancer

Chemists and biologists from the University of Bath have developed a new technique that could be used to diagnose and develop treatments for age-related conditions like Alzheimer's disease, diabetes and cancer.

15 Dec 2009

Pure populations of immature cells that enable male reproduction isolated and transplanted

Reproductive researchers from the University of Pennsylvania and The Children's Hospital of Philadelphia have succeeded in isolating and transplanting pure populations of the immature cells that enable male reproduction in two species-human spermatogonia and mouse gonocytes. These germline stem cells, taken from testis biopsies, demonstrated viability following transplantation to mouse testes within a controlled laboratory setting.

15 Dec 2009

Risks and benefits of CT scans

Doses of radiation from commonly performed computed tomography (CT) scans vary widely, appear higher than generally believed and may contribute to an estimated tens of thousands of future cancer cases, according to two reports in the December 14/28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

15 Dec 2009

Cancer News and Research

Latest Cancer News and Research

USPTO issues Notice of Allowance for U.S. patent application in the 'Crooke' patent family

Zecotek Photonics' proprietary TGFL selected for research in flow cytometry

Stress and alcohol can trigger domestic violence during holiday season

Results from five new studies on Genomic Health's Oncotype DX breast cancer test announced

Dendritic cell changes suggest new strategy to identify and treat debilitating lung disease

BioAlliance Pharma SA to enter Phase II clinical trial for clonidine Lauriad and Phase I clinical trial for AMEP

Advaxis to collaborate with GOG in Phase II clinical trial of ADXS11-001

Lilly Endowment offers $60 million to implement the Indiana Physician Scientist Initiative

University of Wisconsin IRB approves GenSpera's G-202 Phase I study for cancer

Encouraging results from DAVANAT in combination with chemotherapies and biologics

Celgene announces positive data from its apremilast Phase IIb study for plaque-type psoriasis

Novartis submits JOULFERON MAA to the EMEA

Lytix Biopharma AS receives approval to commence Phase I clinical trials of Oncopore

Gamma Medica-Ideas signs exclusive license and commercialization agreement with Mayo Clinic

Teens, contraception and unplanned pregnancy

Preventing tumours from making new blood vessels can also prevent spread of cancer

Decline in reducing youth smoking and increase in smokeless tobacco use

New technique may help diagnose treatments for Alzheimer's, diabetes and cancer

Pure populations of immature cells that enable male reproduction isolated and transplanted

Risks and benefits of CT scans

Understanding the DNA Damage Response in Innate Immunity eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in